388 related articles for article (PubMed ID: 30854496)
1. The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy.
Hoerner CR; Chen VJ; Fan AC
Kidney Cancer; 2019 Feb; 3(1):15-29. PubMed ID: 30854496
[TBL] [Abstract][Full Text] [Related]
2. Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies.
Nguyen TT; Katt WP; Cerione RA
Future Drug Discov; 2023 Mar; 4(4):FDD79. PubMed ID: 37009252
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer.
Matés JM; Di Paola FJ; Campos-Sandoval JA; Mazurek S; Márquez J
Semin Cell Dev Biol; 2020 Feb; 98():34-43. PubMed ID: 31100352
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Segura JA; Alonso FJ; Márquez J
Curr Med Chem; 2020; 27(32):5317-5339. PubMed ID: 31038055
[TBL] [Abstract][Full Text] [Related]
5. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
6. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma.
Kaushik AK; Tarangelo A; Boroughs LK; Ragavan M; Zhang Y; Wu CY; Li X; Ahumada K; Chiang JC; Tcheuyap VT; Saatchi F; Do QN; Yong C; Rosales T; Stevens C; Rao AD; Faubert B; Pachnis P; Zacharias LG; Vu H; Cai F; Mathews TP; Genovese G; Slusher BS; Kapur P; Sun X; Merritt M; Brugarolas J; DeBerardinis RJ
Sci Adv; 2022 Dec; 8(50):eabp8293. PubMed ID: 36525494
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
8. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase inhibition in renal cell carcinoma therapy.
Raczka AM; Reynolds PA
Cancer Drug Resist; 2019; 2(2):356-364. PubMed ID: 35582719
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment.
Fan Y; Xue H; Li Z; Huo M; Gao H; Guan X
Front Pharmacol; 2024; 15():1345522. PubMed ID: 38510646
[TBL] [Abstract][Full Text] [Related]
11. Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies.
Wang Z; Liu F; Fan N; Zhou C; Li D; Macvicar T; Dong Q; Bruns CJ; Zhao Y
Front Oncol; 2020; 10():589508. PubMed ID: 33194749
[TBL] [Abstract][Full Text] [Related]
12. The role of glutaminase in cancer.
Masisi BK; El Ansari R; Alfarsi L; Rakha EA; Green AR; Craze ML
Histopathology; 2020 Mar; 76(4):498-508. PubMed ID: 31596504
[TBL] [Abstract][Full Text] [Related]
13. Altered glutamine metabolism in platinum resistant ovarian cancer.
Hudson CD; Savadelis A; Nagaraj AB; Joseph P; Avril S; DiFeo A; Avril N
Oncotarget; 2016 Jul; 7(27):41637-41649. PubMed ID: 27191653
[TBL] [Abstract][Full Text] [Related]
14. Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer.
Yu Y; Yu X; Fan C; Wang H; Wang R; Feng C; Guan H
J Mol Med (Berl); 2018 Aug; 96(8):777-790. PubMed ID: 29942976
[TBL] [Abstract][Full Text] [Related]
15. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.
Hwang VJ; Kim J; Rand A; Yang C; Sturdivant S; Hammock B; Bell PD; Guay-Woodford LM; Weiss RH
Am J Physiol Renal Physiol; 2015 Sep; 309(6):F492-8. PubMed ID: 26155843
[TBL] [Abstract][Full Text] [Related]
16. Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer.
Ni R; Li Z; Li L; Peng D; Ming Y; Li L; Liu Y
Front Oncol; 2023; 13():1143798. PubMed ID: 36959802
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group.
Chang X; Wang M; Zhang D; Zhang Y; Wang J; Li Z; Bian J; Xu X
Eur J Med Chem; 2023 Jan; 246():115014. PubMed ID: 36525694
[TBL] [Abstract][Full Text] [Related]
18. Glutaminase isoenzymes in the metabolic therapy of cancer.
Matés JM; Campos-Sandoval JA; Márquez J
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):158-164. PubMed ID: 30053497
[TBL] [Abstract][Full Text] [Related]
19. Glutamine metabolic reprogramming in hepatocellular carcinoma.
Ye Y; Yu B; Wang H; Yi F
Front Mol Biosci; 2023; 10():1242059. PubMed ID: 37635935
[TBL] [Abstract][Full Text] [Related]
20. Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
Meijer TWH; Peeters WJM; Dubois LJ; van Gisbergen MW; Biemans R; Venhuizen JH; Span PN; Bussink J
Lung Cancer; 2018 Dec; 126():32-40. PubMed ID: 30527190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
